HDAC1 overexpression reduces chemosensitivity by promoting cell survival and inhibiting apoptotic responses in Luminal A breast cancer cells
This study demonstrates that HDAC1 overexpression in Luminal A breast cancer reduces chemosensitivity to multiple drugs by promoting cell survival and inhibiting apoptosis through the regulation of chromatin remodeling and key signaling pathways like p53/RB1 and NRF2, potentially involving interactions with YY1.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Breast cancer is not a single disease but a collection of related conditions, each with its own personality and behavior. One of the most common types, known as Luminal A, is generally slower-growing and responds well to hormone-blocking treatments. However, for some patients, doctors must turn to chemotherapy, a powerful treatment that uses drugs to kill rapidly dividing cells. The success of chemotherapy depends entirely on whether the cancer cells are sensitive enough to die when exposed to these drugs. Sometimes, the cancer cells develop a way to survive, rendering the treatment ineffective. A key factor in this survival is a group of proteins that act like editors for the cell's genetic instructions. These proteins, called histone deacetylases, can tighten the packaging of DNA, making it harder for the cell to read the instructions that tell it to self-destruct when damaged. When these editors are too active, they can hide the cell's own emergency brakes, allowing the cancer to ignore the damage caused by chemotherapy and keep living.
In a recent study, researchers set out to understand how one specific editor, called HDAC1, influences the fate of Luminal A breast cancer cells when they face chemotherapy. The team, led by scientists from hospitals and universities in China, combined large-scale computer analysis of existing cancer data with new experiments in the laboratory. They began by looking at thousands of patient records to see how much HDAC1 was present in different tumors. They found that this protein was significantly more abundant in breast cancer tissues than in healthy ones. Furthermore, patients whose tumors had high levels of HDAC1 tended to have shorter survival times, suggesting that this protein is linked to more aggressive disease. The researchers then focused on a specific question: does having too much HDAC1 make the cancer cells harder to kill with standard chemotherapy drugs?
To answer this, the scientists created a new version of a common breast cancer cell line, MCF-7, which naturally mimics the Luminal A subtype. They engineered these cells to produce extra HDAC1, essentially turning up the volume on this survival mechanism, and compared them to normal cells that had not been altered. They then exposed both groups to three different chemotherapy drugs: pirarubicin, teniposide, and cisplatin. These drugs work in different ways to damage the DNA of cancer cells, forcing them to either repair the damage or die. The results were clear. The cells with extra HDAC1 were much better at surviving the attack. They required higher doses of the drugs to be killed, and when they were exposed to the same doses as the normal cells, far fewer of them died. The researchers observed that the HDAC1-rich cells were actively blocking the process of programmed cell death, a natural mechanism that usually eliminates damaged cells. Instead of dying, these cells continued to grow and divide, effectively resisting the treatment.
The study also explored how HDAC1 achieves this protection. By analyzing the interactions between proteins, the researchers found that HDAC1 works closely with other key regulators that control the cell cycle and DNA repair. They used computer modeling to predict how HDAC1 might physically connect with another protein called YY1, a connection that could help silence the genes responsible for cell death. The simulations suggested that these two proteins form a stable complex, working together to keep the cell's defenses up. Additionally, the team looked at the broader environment around the tumor. They discovered that high levels of HDAC1 were associated with changes in the immune system's presence within the tumor. Specifically, the protein seemed to correlate with the activity of certain immune cells and checkpoint molecules that can sometimes help tumors hide from the body's natural defenses. This suggests that HDAC1 might not only protect the cancer cell from the inside but also help it manipulate the surrounding environment to avoid detection and destruction.
The researchers concluded that HDAC1 acts as a shield for Luminal A breast cancer cells, helping them survive chemotherapy by suppressing the signals that would normally trigger their death. While the study was conducted in a laboratory setting using cell cultures, the findings point to a clear mechanism: when HDAC1 is overactive, it helps the cancer ignore the damage caused by drugs. The study did not test this in living patients, and the researchers noted that their work was limited to this specific cell type, meaning the results might differ in other forms of breast cancer. However, the evidence strongly suggests that targeting HDAC1 could be a promising strategy. If doctors could find a way to turn down the activity of this protein, they might be able to strip away the cancer's defenses, making the cells vulnerable again to standard chemotherapy. This approach could potentially turn a resistant tumor back into one that responds to treatment, offering new hope for patients whose cancer has stopped listening to the drugs meant to cure them.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.